$340 Million is the total value of Ally Bridge Group (NY) LLC's 31 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 48.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Buy | NATERA INC | $29,866,000 | +20.7% | 268,000 | +22.9% | 8.78% | +42.8% |
| SPDR SER TRput | $25,142,000 | -7.2% | 200,000 | 0.0% | 7.39% | +9.9% | ||
| RGEN | Sell | REPLIGEN CORP | $20,229,000 | +22.8% | 70,000 | -15.2% | 5.95% | +45.4% |
| ARVN | Sell | ARVINAS INC | $17,258,000 | -6.6% | 210,000 | -12.5% | 5.07% | +10.5% |
| MRTX | MIRATI THERAPEUTICS INC | $16,806,000 | +9.5% | 95,000 | 0.0% | 4.94% | +29.6% | |
| NUVB | Sell | NUVATION BIO INC | $16,510,000 | +3.8% | 1,660,947 | -2.8% | 4.85% | +22.9% |
| FATE | FATE THERAPEUTICS INC | $16,003,000 | -31.7% | 270,000 | 0.0% | 4.70% | -19.2% | |
| SYRS | SYROS PHARMACEUTICALS INC | $15,376,000 | -18.0% | 3,439,895 | 0.0% | 4.52% | -2.9% | |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $14,887,000 | -5.3% | 904,978 | +5.2% | 4.38% | +12.0% |
| GOSS | GOSSAMER BIO INC | $14,770,000 | +54.8% | 1,175,000 | 0.0% | 4.34% | +83.2% | |
| IDYA | Buy | IDEAYA BIOSCIENCES INC | $14,681,000 | +37.0% | 575,940 | +12.8% | 4.32% | +62.2% |
| COGT | COGENT BIOSCIENCES INC | $13,646,000 | +3.7% | 1,622,591 | 0.0% | 4.01% | +22.7% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $10,036,000 | -5.2% | 406,986 | 0.0% | 2.95% | +12.2% | |
| New | SOMALOGIC INC | $9,912,000 | – | 800,000 | +100.0% | 2.91% | – | |
| APELLIS PHARMACEUTICALS INCcall | $9,888,000 | -47.8% | 300,000 | 0.0% | 2.91% | -38.3% | ||
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $9,210,000 | -39.2% | 1,500,000 | 0.0% | 2.71% | -28.1% | |
| NSTG | NANOSTRING TECHNOLOGIES INC | $8,882,000 | -25.9% | 185,000 | 0.0% | 2.61% | -12.3% | |
| NTLA | Sell | INTELLIA THERAPEUTICS INC | $8,720,000 | -42.2% | 65,000 | -30.2% | 2.56% | -31.6% |
| MDVL | MEDAVAIL HOLDINGS INC | $8,529,000 | -76.2% | 2,920,780 | 0.0% | 2.51% | -71.8% | |
| New | RAPID MICRO BIOSYSTEMS INC | $8,089,000 | – | 437,960 | +100.0% | 2.38% | – | |
| New | SIGHT SCIENCES INC | $7,770,000 | – | 342,304 | +100.0% | 2.28% | – | |
| MGNX | Buy | MACROGENICS INC | $7,643,000 | +152.2% | 365,000 | +223.5% | 2.25% | +198.4% |
| NVTA | Sell | INVITAE CORP | $5,683,000 | -43.8% | 199,900 | -33.4% | 1.67% | -33.5% |
| CYT | Sell | CYTEIR THERAPEUTICS INC | $5,608,000 | -58.2% | 319,538 | -49.0% | 1.65% | -50.5% |
| AMRS | New | AMYRIS INC | $4,839,000 | – | 352,445 | +100.0% | 1.42% | – |
| LPTX | New | LEAP THERAPEUTICS INC | $4,812,000 | – | 1,200,000 | +100.0% | 1.42% | – |
| ISEE | New | IVERIC BIO INC | $4,060,000 | – | 250,000 | +100.0% | 1.19% | – |
| BLI | New | BERKELEY LTS INC | $3,951,000 | – | 201,996 | +100.0% | 1.16% | – |
| ACET | ADICET BIO INC | $3,332,000 | -23.8% | 425,000 | 0.0% | 0.98% | -9.8% | |
| BOLT | Sell | BOLT BIOTHERAPEUTICS INC | $3,254,000 | -48.9% | 257,267 | -37.6% | 0.96% | -39.6% |
| VERV | New | VERVE THERAPEUTICS INC | $705,000 | – | 15,000 | +100.0% | 0.21% | – |
| FRLN | Exit | FREELINE THERAPEUTICS HLDGSsponsored ads | $0 | – | -401,747 | -100.0% | -0.81% | – |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -128,572 | -100.0% | -0.99% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -85,000 | -100.0% | -1.34% | – |
| AVIR | Exit | ATEA PHARMACEUTICALS INC | $0 | – | -373,288 | -100.0% | -1.99% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -363,185 | -100.0% | -2.58% | – |
| CERE | Exit | CEREVEL THERAPEUTICS HLDNG I | $0 | – | -675,670 | -100.0% | -4.30% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.